{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:27:55Z","timestamp":1787185675195,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcjo.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:12:01Z","timestamp":1778245921000},"page":"990-998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-490X","authenticated-orcid":false,"given":"Sara Kamali","family":"Zonouzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5948-0331","authenticated-orcid":false,"given":"Michael","family":"Balas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-2245","authenticated-orcid":false,"given":"Parnian","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.02.010_bib0001","unstructured":"U.S. Food and Drug Administration. EYLEA (aflibercept) approval letter and review documents. Drugs@FDA. Accessed July 7, 2025. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0002","unstructured":"U.S. Food and Drug Administration. LUCENTIS\u00ae (ranibizumab injection) for intravitreal injection. Drugs@FDA. Accessed January 12, 2026. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0003","unstructured":"U.S. Food and Drug Administration. BEOVU\u00ae (brolucizumab-dbll) injection, for intravitreal injection. Drugs@FDA. Accessed January 12, 2026. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0004","unstructured":"US Food and Drug Administration website. VABYSMO\u00ae (faricimab-svoa) injection, for intravitreal use. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0007","unstructured":"U.S. Food and Drug Administration. EYLEA HD (aflibercept 8 mg) approval letter and review documents. Drugs@FDA Accessed Febuary 11, 2026. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0008","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.2147\/OPTH.S489114","article-title":"Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review","volume":"18","author":"Aldokhail","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/24741264251332515","article-title":"Intraocular inflammation, safety events, and outcomes after intravitreal injection of ranibizumab, aflibercept, brolucizumab, abicipar pegol, and faricimab for nAMD","author":"Stevanovic","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0011","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0012","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO Trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0013","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4082\/kjfm.21.0193","article-title":"Pharmacovigilance and its importance for primary health care professionals","volume":"43","author":"Hamid","year":"2022","journal-title":"Korean J Fam Med"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.720345","article-title":"Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice","volume":"12","author":"Montesel","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0015","unstructured":"U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard. Accessed July 7, 2025. n.d."},{"key":"10.1016\/j.jcjo.2026.02.010_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0018","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-12-2911","article-title":"Aflibercept","volume":"19","author":"Ciombor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12859-019-2628-5","article-title":"Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA","volume":"20","author":"Wu","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0022","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0023","doi-asserted-by":"crossref","unstructured":"Lakhani M, Popovic MM, Al-Ani A, et al. Comparative analysis of ocular adverse events associated with aflibercept 8 mg and faricimab: a global population-based study across 65 countries. Ophthalmol Retina In press. https:\/\/doi.org\/10.1016\/j.oret.2025.10.019.","DOI":"10.1016\/j.oret.2025.10.019"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0024","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.oret.2019.03.012","article-title":"Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: The AQUA study","volume":"3","author":"Garweg","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.010_bib0027","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:20:51Z","timestamp":1787185251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0008418226000785"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.02.010","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}